Circulating Cell-Free Tumor DNA Market Estimated To Witness High Growth Owing To Wide Applications In Cancer Research And Diagnostics

Circulating Cell-Free Tumor DNA Market

 The global Circulating Cell-Free Tumor DNA Market is estimated to be valued at US$ 6.1 Bn in 2023 and is expected to exhibit a CAGR of 22% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.

 

Market Overview:

Circulating cell-free tumor DNA (ctDNA) are fragments of tumor DNA that are shed by tumors into the bloodstream. Detection of ctDNA is important for early cancer detection and monitoring disease progression and response to treatment in various cancer types.

 

Market key trends:

One of the key trends in the circulating cell-free tumor DNA market is the increasing application of ctDNA analysis for non-invasive cancer monitoring. CtDNA analysis allows repeated sampling thus enabling real-time monitoring of tumor burden and genomic alterations during and after systemic therapies. This provides crucial information on treatment response and development of resistance which enables timely modification of treatment regimen. CtDNA analysis also aids in early detection of relapse and metastatic spread of cancer without invasive tissue biopsies. This non-invasive approach has gained popularity as it offers several advantages over traditional tumor tissue biopsies.

Segment Analysis

The circulating cell-free tumor DNA market is dominated by the liquid biopsy sub-segment due to the fact that liquid biopsy tests have advantages over traditional tumor tissue biopsies. These advantages include being less invasive, allowing for repeated sampling, and providing a better representation of overall tumor heterogeneity as circulating tumor DNA comes from all tumor sites rather than a single site.

 

Key Takeaways

The Global Circulating Cell-free Tumor DNA Market Size is expected to witness high growth, exhibiting a CAGR of 22% over the forecast period, due to increasing incidence of cancer globally.

 

Regional analysis

North America dominated the global circulating cell-free tumor DNA market in 2023 owing to increasing investments in cancer research and advanced healthcare infrastructure in the region. However, Asia-Pacific is expected to grow at the fastest CAGR during the forecast period due to rising healthcare expenditure and growing awareness regarding liquid biopsies.

 

Key players

Key players operating in the circulating cell-free tumor DNA market are Biocept, Inc., Illumina, Inc., Quest Diagnostics Incorporated, KURABO INDUSTRIES LTD, PerkinElmer chemagen Technologie GmbH, Biodesix, Guardant Health, QIAGEN, Sequenom, Inc., Agilent Technologies, Inc., Fluxion Biosciences Inc., Natera, Inc., Agena Bioscience, Inc., Paragon Genomics, Inc., Lucence Health Inc., Eurofins Genomics, Thermo Fisher Scientific.

Read More

https://www.dailyprbulletin.com/circulating-cell-free-tumor-dna-market-size-share-growth-outlook-2023/